sentiment_stocks,
Based on the numbers, they did have control patients enrolled. They had 87(?) total, 29 control, planned for to be enrolled and only 17 total remained unenrolled and Germany was very likely the last to fully enroll treatment arm patients. That means 10 were very likely enrolled and of those several likely PFS evented quickly along with possible pseudoprogression treatment response in the treatment arm which would have been seen as an immediate potential safety issue by German regulators and FDA. Some of those control patients probably never fully recovered while the treatment arm patients did better. Remember that the interim data from 2018 suggested that some of the long livers came from low absolute lymphocyte count patients and those could have been enrolled in Germany in late 2014 to early 2015 ; ). Best wishes.
Market Data 
Markets 
AI
